May 15, 2017—UC San Diego Altman Clinical and Translational Research Institute (ACTRI) is pleased to announce the availability of Pilot Project Grants for 2018. These grants are one-year awards (up to $30,000) to provide funding for early stage projects. The award categories are: Clinical and Translational Research; and Life Course Research.
Trial Innovation Network Launched to Facilitate Multi-site Clinical Studies
ACTRI is a TIN Hub Liaison Team
April 4, 2017—The Clinical and Translational Science Awards (CTSA) program has launched the Trial Innovation Network (TIN) to facilitate multi-site clinical studies and is seeking Network proposals. UC San Diego Altman Clinical and Translational Research Institute (ACTRI), funded in part through a CTSA grant, is a TIN Hub Liaison Team and is available for consultation on Network proposals.
The Trial Innovation Network addresses critical roadblocks in clinical trials and accelerates the translation of novel interventions into life-saving therapies. The Network focuses on operational innovation, operational excellence, and collaboration while leveraging the expertise and resources of the CTSA Program. Features include a single institutional review board system, master contracting agreements, quality-by-design approaches, and a focus on evidence-based strategies to recruitment and patient engagement. Key TIN elements for increasing efficiency and flexibility of multi-site studies are the single IRB reliance using the SMART IRB Exchange and the utilization of master/standard agreements.
The Trial Innovation Network is accepting Network Project Proposals for basic consultation or services, or comprehensive consultation. The Network prioritizes proposals for multi-center clinical trials and studies with patient-oriented endpoints with potential for impact on clinical practice and operational innovation.
UC San Diego investigators are required to contact the ACTRI Hub Liaison Team to discuss their TIN proposal and submit it for a pre-review by the ACTRI Scientific Review Committee. Please contact ACTRI team medical director Mark S. Wallace or team project manager Archana Bhatt to begin the consultation and pre-review process. These initial consultations provide guidance in developing your Network project proposal to the NIH.
Learn more about the Trial Innovation Network and the ACTRI Hub Liaison Team
March 14, 2017— A webinar, “Lessons Learned with Implementation of a Pragmatic Trial of Physical Activity Coaching in COPD,” will be presented by Dr. Huong Q. Nguyen on Wednesday, April 5, from Noon to 1 P.M.
February 28, 2017–UC San Diego Altman Clinical and Translational Research Institute (ACTRI) and the Institute of Engineering in Medicine (IEM) invite engineers to submit proposals for Phase II of the Galvanizing Engineering in Medicine (GEM) awards. The GEM challenge is composed of two phases with the overarching goal of building a collaborative ecosystem that leverages UC San Diego’s outstanding strengths in clinical care and engineering to develop and implement innovative healthcare solutions. Phase I of the competition invites clinically active UC San Diego faculty to submit a proposal identifying a specific challenge in patient care that is amenable to an innovative engineering solution. Phase II of the competition invites engineers to propose solutions to the top ranking Phase I proposals, with the aim of incentivizing engineers to work with clinicians to solve some of the most pressing challenges.
January 31, 2017 – The University of California-OptumLabs partnership was established to help accelerate improvements in patient care and value. The 10-year strategic relationship will help transition California to a value-based health care system while leveraging the expertise of each organization to examine broader trends in care delivery. As part of the strategic relationship between UC and OptumLabs, OptumLabs will provide up to 7 UC researchers with complimentary access (aka: “research credits”) to its data warehouse. We are soliciting proposals for research ideas that leverage the OptumLabs data.